Pr3vent, which is developing artificial intelligence for early detection of preventable vision loss in healthy term newborn infants, closed a round of Series A financing led by InFocus Capital Partners.
“This financing round puts Pr3vent in a strong position to create a profitable AI solution in the ophthalmic space,” Pr3vent CEO Jochen Kumm, PhD, said in a press release.
The Pr3vent AI technology is under development as a noninvasive retinal screening tool intended to identify pathology in newborns.
“We are in the process of finalizing our database curation and our algorithm,
Uncategorized